Prevent III score as a predictor of limb salvage and mortality after aortoiliac revascularization

• Type: Article in International Scientific Journal
• Date: 2024

Authors

Romana Dias, L (Author) Other; Alves, D (Author) Other; Vidoedo, J (Author) Other; Rocha Neves, J (Author) FMUP; Andrade, JP (Author) Other; Pereira Neves, A (Author) Other

Journal

Title: Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery

Vol. 32

Pages: 253-260

ISSN: 1301-5680

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-012-PGE

DOI: 10.5606/tgkdc.dergisi.2024.26066

Abstract (EN): Background: This prospective study aimed to validate the prognostic value of Prevent III (PIII) risk score in patients undergoing aortoiliac revascularization, both in limb-related outcomes and cardiovascular risk. Methods: The prospective cohort study included 130 consecutive patients (122 males, 8 females; mean age: 62.1 +/- 9.2 years; range, 53 to 71 years) undergoing elective aortoiliac revascularization between January 2013 and September 2022. Patients' demographic and clinical characteristics were retrieved and PIII scores were calculated. A risk category was assigned according to the total points: low-risk (score <= 3), medium-risk (score 4-7), or high-risk (score >= 8). Results: The median follow-up period was 55 months (interquartile range, 39 to 70 months). Twenty-four (18.5%) patients had a PIII score >= 4. Regarding short-term outcomes, patients with PIII scores >= 4 exhibited lower ankle-brachial index changes at 30 days and more extended hospital stays. There were no significant associations between PIII scores and major adverse events at 30 days. However, during follow-up, a PIII score >= 4 was associated with increased major adverse limb events (p=0.036) and all-cause mortality (p=0.007). Conclusion: The PIII score is a reliable predictor of long-term limb and mortality risk in patients undergoing aortoiliac revascularization procedures, leveraging five user-friendly clinical parameters. More research with larger cohorts and studies comparing PIII with other validated scores should be performed in the future.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 8